BVXV innovative COVID-19 nanosized antibodies
BiondVax has signed definitive agreements with the Max Planck Society and the University Medical Center Göttingen to enter into a strategic collaboration for the development and commercialization of innovative COVID-19 nanosized antibodies (NanoAbs).
NanoAbs exhibited in-vitro neutralization of all COVID-19 variants of concern including Delta, and based on in-silico studies, Omicron, at significantly lower dose levels than existing antibody treatments.
i know that this is an early stage, but today they announced also that the Former CFO of GSK's Global Vaccines Business Mr. Jay Green Joins BiondVax's Board of Directors.
just to make an idea, GSK has a Market Cap of 111Bil and Jay Green went to a company that has a mk cap of 35Mil.
They also had a public offering at the price of $2.36.
52 Week Range 1.36 - 7.22
My price target is $6
NanoAbs exhibited in-vitro neutralization of all COVID-19 variants of concern including Delta, and based on in-silico studies, Omicron, at significantly lower dose levels than existing antibody treatments.
i know that this is an early stage, but today they announced also that the Former CFO of GSK's Global Vaccines Business Mr. Jay Green Joins BiondVax's Board of Directors.
just to make an idea, GSK has a Market Cap of 111Bil and Jay Green went to a company that has a mk cap of 35Mil.
They also had a public offering at the price of $2.36.
52 Week Range 1.36 - 7.22
My price target is $6
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
Private Signals patreon.com/PremiumOptionsSignals
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
TRADING COURSE bit.ly/tradex
Private Signals patreon.com/PremiumOptionsSignals
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.